We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Aquestive Therapeutics (AQST - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Aquestive Therapeutics is a member of our Medical group, which includes 1144 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aquestive Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AQST's full-year earnings has moved 55.7% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AQST has returned about 146.1% since the start of the calendar year. At the same time, Medical stocks have lost an average of 4.4%. This shows that Aquestive Therapeutics is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Corvus Pharmaceuticals (CRVS - Free Report) . The stock has returned 229.4% year-to-date.
In Corvus Pharmaceuticals' case, the consensus EPS estimate for the current year increased 32.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Aquestive Therapeutics is a member of the Medical - Drugs industry, which includes 208 individual companies and currently sits at #110 in the Zacks Industry Rank. This group has lost an average of 3.9% so far this year, so AQST is performing better in this area.
On the other hand, Corvus Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry. This 552-stock industry is currently ranked #110. The industry has moved -8.7% year to date.
Aquestive Therapeutics and Corvus Pharmaceuticals could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Aquestive Therapeutics (AQST - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Aquestive Therapeutics is a member of our Medical group, which includes 1144 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aquestive Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AQST's full-year earnings has moved 55.7% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AQST has returned about 146.1% since the start of the calendar year. At the same time, Medical stocks have lost an average of 4.4%. This shows that Aquestive Therapeutics is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Corvus Pharmaceuticals (CRVS - Free Report) . The stock has returned 229.4% year-to-date.
In Corvus Pharmaceuticals' case, the consensus EPS estimate for the current year increased 32.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Aquestive Therapeutics is a member of the Medical - Drugs industry, which includes 208 individual companies and currently sits at #110 in the Zacks Industry Rank. This group has lost an average of 3.9% so far this year, so AQST is performing better in this area.
On the other hand, Corvus Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry. This 552-stock industry is currently ranked #110. The industry has moved -8.7% year to date.
Aquestive Therapeutics and Corvus Pharmaceuticals could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.